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in order to increase translation efficiency. Typically, such 
modification adds several days to the protocol. 
A more desirable system which would greatly reduce the 
time period for production of significant amounts of protein 
5 would include the ability to continuously amplify the mRNA 
template, the DNA template, and synthesize protein in a 
single system. In so doing, the amount of both the mRNA 
transcripts and the DNA from which the mRNA transcripts 
are transcribed would increase, thereby continually increas- 
In vitro, the synthesis of double-stranded DNA from 
mRNA, the synthesis of mRNA from DNA, and the trans- 
lation of mRNA into protein proceed by different 
mechanisms, utilizing different enzymes and different reac- 
tion conditions (e.g., buffers, temperature, time periods, 
cofactors). To date, reaction conditions which allow trans- 
lation of mRNA and those which allow polynucleotide 
amplification have been incompatible. Therefore, although it 
would be highly desirable, it would be unexpected to suc- 
2o cessfully devise a single unified system whereby RNA 
amplification and in vitro translation could proceed under a 
single set of reaction conditions without the continuous 
input of new complex components, such as polynucleotide, 
or the removal of product. The present invention solves the 
25 problems of the prior art by providing a novel system 
wherein the reaction conditions are compatible with isother- 
mal RNA amplification and in vitro translation proceeding 
simultaneously. 
10 ing the yield of protein. 
30 SUMMARY OF THE INVENTION 
The present invention provides a novel cell-free system 
whereby polynucleotide amplification and in vitro transla- 
tion proceed simultaneously under a common set of reaction 
35 conditions. Prior to the development of the invention, such 
a unified coupled system did not exist and was not thought 
possible because synthesis of mRNA to DNA, transcription 
of mRNAfrom DNA, and translation of mRNAinto protein, 
occur under such distinct, and typically mutually hostile, 
40 conditions. Factors such as differences in temperature, 
buffers, and enzymes previously had made the utilization of 
a single, unified, simultaneous reaction system for poly- 
nucleotide amplification and translation unattainable. 
Consequently, it was heretofore extremely time-consuming 
45 to synthesize large quantities of protein for commercial and 
other purposes. 
The invention addresses the failings of the prior art by 
providing a unified system which allows the necessary 
biosynthetic reactions to take place quickly and efficiently in 
50 a single vessel at a constant temperature. Also included is a 
buffer composition which allows the system to proceed at a 
high level of efficiency. 
BRIEF DESCRIPTION OF THE DRAWINGS 
55 FIG. 1 shows isothermal amplification of RNA in the 
presence of varying concentrations of MgC1, in the coupled 
system. [a-32P]-GTP was included to show incorporation 
into newly synthesized RNA. 
FIG. 2 shows in vitro translation of RNA in the presence 
of varying concentrations of MgCl,, in the coupled system. 
35S-methionine was included to show incorporation into 
protein. 
6o 
DETAILED DESCRIPTION 
65 
The present invention provides a cell-free system for 
polynucleotide amplification and in vitro translation where 
1 
COUPLED ISOTHERMAL 
POLY NUCLEOTIDE AMPLIFICATION AND 
TRANSLATION SYSTEM 
This is a continuation of application Ser. No. 071939,302 
filed on Sep. 2, 1994, now abandoned. 
This invention was made with Government support 
under Grant No. NASA Grant #NAGW-2881 awarded by 
the National Aeronautics and Space Administraton. The 
Government has certain rights in this invention. 
BACKGROUND 
1. Field of the Invention 
This invention relates generally to the transcription, 
amplification and translation of nucleotides. Specifically, the 
invention relates to a system whereby polynucleotide ampli- 
fication and in vitro translation occur spontaneously under 
the same reaction conditions. 
2. Description of Related Art 
Expression of foreign genes in living cells is often subject 
to a number of limitations. A major limitation on in vivo 
production of polypeptides is where the polypeptide is 
unstable or, in some cases, toxic to the cell. For example, 
various proteases, immunotoxins, or lectins cannot be safely 
produced using such in vivo systems. 
In light of the significant drawbacks associated with in 
vivo polypeptide expression, there has been considerable 
interest in developing in vitro expression systems. However, 
a major limitation with the cell-free translation systems 
described to date is the low yield of the polypeptide product 
produced. This low yield may be due to factors such as the 
lability and short half-life of mRNA in these systems. 
Typically only two to three polypeptide chains are produced 
for each mRNA chain used in such systems. One way to 
compensate for this low yield is to use large amounts of 
pre-synthesized mRNA, although the supply of mRNA is 
soon expended such that more pre-synthesized mRNA must 
be supplied to maintain production of polypeptide. 
Several continuous cell-free translation systems theoreti- 
cally capable of producing polypeptides in high yield have 
been developed (Spirin, et al., Science, 242:1162, 1988; 
Ryabova, et al., Nucl. Acids Res., 17:4412, 1989). These 
systems prolong the functioning of a cell-free translation 
system. However, the reaction products, including synthe- 
sized polypeptides, must be continuously removed from the 
reaction mixture, and the initial concentrations of low 
molecular weight substrates must be continuously restored. 
In addition, although continuous cell-free translation sys- 
tems produce high yields of synthesized protein, these 
systems have the disadvantage of doing so only over long 
periods of time. Typically, these systems require 10 to 100 
hours to produce larger quantities of protein. Existing in 
vitro translation systems have the further disadvantage of 
requiring prior synthesis of large amounts of mRNA using 
either T7 or SP6 polymerases. This can be costly and 
introduce extra steps into the protocol. 
More recently, coupled transcription-translation systems 
have been studied which retain the advantages of a cell-free 
translation system and use DNA molecules directly as 
templates for transcription and subsequent translation. 
However, this coupled system still requires the cloning of 
cDNA or genomic DNA lacking introns into an expression 
vector containing the T7 or SP6 promoter, for example. As 
a result, it is usually necessary to modify the initial cDNA 
or genomic clone to optimize the length of the 5' or 3' 
untranslated sequence adjacent to the protein coding region 
5,807,717 
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the components of the system function under a common set the RNA template is called complementary DNA (cDNA). 
of reaction conditions. The system includes an RNA- The term “primer” as used herein refers to a sequence 
dependent DNApolymerase, a polynucleotide primer which comprising two or more deoxyribonucleotides or 
allows the RNA-dependent DNA polymerase to function, a ribonucleotides, preferably at least eight, which sequence is 
DNA-dependent RNA polymerase, a polynucleotide primer 5 capable Of initiating synthesis Of an extension product, and 
which allows the DNA-dependent RNA polymerase to which is substantially complementary to a target nucleic 
function, deoxyribonucleotide triphosphate, ribonucleoside acid strand. The Primer typically contains 15-22 or more 
The coupled isothermal polynucleotide amplification and in Of such oligodeoxynucleotide primers Of the 
vitro translation system of the invention is a unified system 10 invention include, but are not limited to, an o k o  (dT) 
which does not require temperature cycling or similar com- polymer, a collection Of random DNA sequences, Or a 
plex manipulation. The invention also provides a buffer specific sequence. An Olig0 (dT) polymer can be to 
solution which is used in conjunction with the cell-free prime the cDNAsynthesis from the polyA Of any mRNA 
system to achieve efficient in vitro transcription, amplifica- having a Poly A region. If the sequence of the mRNA is 
triphosphate and a cell-free in vitro translation composition, nucleotides, although it may contain fewer nucleotides. 
tion and in vitro translation. 15 unknown, or if it is desirable to account for degeneracy in 
the mRNA sequence, a collection of random DNA The ability to produce substantial quantities of protein by sequences can alternatively be used. Further, if the sequence in vitro DNA synthesis and transcription has several impor- of the mRNA which is to be amplified and translated is tant applications. It allows production of proteins that would known, a specific sequence primer can be utilized to allow be toxic or unstable in vivo. It also allows incorporation of initiation of cDNA synthesis from that specific sequence on non-standard amino acids into protein via addition of appro- 20 the mRNA. Preferably the primer which allows RT to priate t R N A  to the reaction milieu. In vitro production of function is complementary to sequences at the 3’-terminal combinatorial libraries of polypeptides based on translation region of the mRNA, although the invention also includes of a mixed population of synthetic mRNAs can also be primers which extend into the non-translated portion of the 
mRNA. achieved. 
“DNA-dependent RNA polymerase” as used herein, 
non-living extract for use in amplification of polynucleotides refers to an enzyme which synthesizes mRNA transcripts 
and translation in vitro. The cell-free system contains all from DNA, DNA-dependent RNA polymerases used in the 
factors required for the translation of mRNA, for example invention include but are not limited to E, RNA poly- 
tors and initiation factors. Typically, exogenous mRNA of 30 polymerase of the invention is derived from the class of 
interest is added to the cell-free system to initiate the bacteriophage RNA polymerases which are encoded by 
The term “cell-free system” refers to a preparation of a 25 
ribosomes, aminoacyl synthetases, fat- merase and bacteriophage RNA polymerase, The preferred 
amp1ification cyc1e, members of a related family of bacteriophages which 
be used. includes T7, T3, and Sp6, Each RNApolymerase is a single 
germ (Roberts, et al.9 Pl‘oc.NatlAcad.Sci. USA, 70123302 35 subunit enzyme that recognizes a specific promoter 
1973) Or et J.  Biochem., sequence, Each RNA polymerase initiates transcription spe- 
67:247, 1976) extracts can be made devoid Of active endog- cifically and exclusively from its own promoter sequence, 
DNA, such as cDNA, can 
systems known in the art, such as wheat 
enous mRNA by treatment with micrococcal nuclease and, 
therefore, provide a system whereby only the input mRNA 
of interest is translated. 
“Polynucleotide amplification” refers to the continuous 
ond strand complementary DNAsynthesis, and transcription 
The preferred RNA polymerase of the invention is the 7”7 
polymerase, 
As used herein, the “polynucleotide primer which allows 
the DNA-dependent RNA polymerase to function” refers to 
otides c o m p ~ e m e n t a r y  to a single-stranded DNA 
40 
cycle of single-stranded DNA synthesis from mRNA, set- a oligodeoxynucleotide sequence which contains nu&- 
Of mRNA from the DNA. In the present invention, (synthesized from mRNA by RT, for example) and contains 
reaction products are amp1ified every time the cyc1e pro- 45 a sequence which is recognized by a DNA-dependent RNA 
ceeds. A polynucleotide refers to a polymer Of deoxyribo- polymerase. Preferably, the primer of this invention contains 
nucleotides or ribonucleosides. a specific sequence for the second-strand of DNA to be 
“RNA-dependent DNA polymerase” denotes an enzyme synthesized, adjacent to nucleotides which encode a DNA- 
which is capable of synthesizing DNA from an RNA dependent RNA polymerase promoter region. For example, 
template, such as reverse transcriptase (RT). RT is derived 50 the preferred RNA polymerase of the invention is T7 poly- 
RT first synthesizes a single-stranded DNA copy of the contain sequences for the T7 promoter region. Thus, the 
mRNA (cDNA) and then incorporates nucleotides to syn- newly synthesized double-stranded DNA molecule contains 
thesize the second complementary strand of DNA. RTs of a T7 promoter and can be efficiently transcribed to the 
the invention include but are not limited to Moloney murine 55 corresponding mRNAby T7 RNApolymerase. Oligodeoxy- 
leukemia virus (MOMLV) RT and Avian myeloblastosis nucleotide primers which allow the DNA dependent RNA 
virus (AMV) RT. Preferably, MoMLV RT is utilized. RT polymerase to function are most preferably complementary 
may also contains a DNA-directed DNApolymerase activity to the 3’-terminal region of the single-stranded cDNA. 
and RNase H activity which degrades RNAin an RNA:DNA Therefore, the newly synthesized second strand of DNA 
hybrid. Other known enzymes which possess the activities 60 would contain the 7”7 promoter sequence at the 5’-terminal 
inherent to a RNA-dependent DNApolymerase are included region. 
in the invention. The primers which allow the DNA-dependent RNApoly- 
As used herein, a “polynucleotide primer which allows merase to function can be a collection of random primers 
the RNA-dependent DNA polymerase to function” refers to rather than one specific sequence. A specific species of 
a oligodeoxynucleotide which allows extension of the DNA 65 mRNA of interest can be included in the reaction mixture 
being synthesized by the RNA-dependent DNA polymerase and, by designing primers which selectively bind to that 
from an RNA template. The DNA synthesized by RT from particular mRNA, larger quantities of the desired protein can 
from retroviruses and is used to make DNA copies of RNA. merase and, therefore, the corresponding primer would 
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be produced. For example, if a small amount of protein is invention include species of Sulfolobus, Thermoproteus, 
isolated, it can be microsequenced by methods known in the Halobacterium, Methanospirillum, Methanobacterium and 
art. From this sequence, primers can be designed that will Methanococcus, for example. Eubacterial cells of the inven- 
select the desired mRNAfor amplification and translation in tion include true bacteria of the gram positive and gram 
the system of the invention. To account for degeneracy, in s negative classes, such as species of Flavobacterium, 
that more than one codon can code for a particular amino Pseudomonas, Escherichia, Agrobacterium, Bacillus, and 
acid, an appropriate collection of primers should be used. Anacystis. Preferably the eubacterial cell of the invention is 
Alternatively, if the class of proteins, for example kinases, is gram negative and, more specifically, is Escherichia coli. 
known, and a COnSenSuS sequence within the mRNA is The cell-free in vitro translation composition of the inven- 
known for that class, specific Primers can be designed to 10 tion can also be derived from a eukaryotic cell. Eukaryotic 
select only mRNAs in that class. cell-free compositions known in the art translate mRNAs 
Oligodeoxynucleotide primers of the invention are chemi- from viral or eukaryotic origin efficiently. Examples of such 
cally synthesized by any of the methods in the art. The systems include those derived from animal cells such as 
oligodeoxynucleotides are most advantageously prepared by Krebs I1 ascites tumor, rat and mouse liver, Hela cells, 
utilizing any of the commercially available, automated 15 mouse L cells, Chinese hamster ovary (CHO) cells, and 
nucleic acid synthesizers. Conventional phosphotriester reticulocytes. Preferably the in vitro translation composition 
(Edge, et al., Nature, 292:756, 198l), phosphodiester or of the invention is derived from a eukaryote, specifically, an 
phosphoramidite (Beaucage, et al., Tet Letts, 22:1859 1981) animal cell. More specifically, the system is derived from a 
methods can be used to prepare synthetic oligodeoxynucle- rabbit reticulocyte. The rabbit reticulocyte lysate from 
otide primers. While any length oligonucleotide may be 20 Promega Biotec (TNT, Madison, Wis.) has been found to be 
utilized in the practice of the invention, sequences shorter particularly useful and is preferred according to the inven- 
than 2 bases may be less specific in hybridizing to the target tion. 
mRNA. Hence, hybridizing oligonucleotides having 15 or The cell-free in vitro composition of the invention also 
more nucleotides are Preferred. Sequences longer that 30 includes a composition derived from a plant cell. Examples 
nucleotides may also be somewhat less effective in binding 25 of such compositions include but are not limited to wheat 
specifically to the target mRNA. Thus, hybridizing OkO- cells, and in particular wheat germ, and rye embryo. Pref- 
mers of 15-20 nucleotides are most preferred in the practice erably the cell-derived composition is from a wheat 
of the present invention. The exact length of the primer cell, 
nucleotide composition but can be determined by routine 30 nents which function under a set of reaction 
conditions. This refers to the ability of cell-free polynucle- experimentation. 
Primers used according to the method of the invention are otide (DNA and RNA) amplification and in vitro translation 
designed to be ‘‘SubstantiallY’’ complementary to each strand to operate in the same buffer, at a constant temperature, and 
of nucleotide sequence to be amplified. Substantially for the same period of time. These conditions allow the DNA 
complementary means that the Primers must be sufficiently 35 template and corresponding mRNA to be continually ampli- 
complementary to hybridize with their respective strands fied in the Same reaction that allows the m~~~ to be 
under conditions which allow the agent for PolYmerization translated into protein. In contrast to the known continuous 
to function. Preferably, the terminus of the Primer that is transcription-in vitro translation systems, the present inven- 
extended has Perfectly base Paired complementarity with the 4o tion offers the advantage of the production of large quantities 
complementary flanking strand. of protein in a short period of time, without the need for 
The deoxyribonucleotide (dNTP) and ribonucleoside continually manipulating the system, for example, by the 
(rNTP) triphosphate of the invention include ATP, GTP, TTP addition of complex components such as in mRNA and 
(UTP for ribonucleoside), and CTP. These are included in cDNA. 
the cell-free system for incorporation by the DNA and RNA 45 The “solution useful for the operation of the cell-free 
Polymerases into DNAand RNAresPectivelY. It may also be system” refers to the composition which allows polynucle- 
desirable for the RNA synthesized to contain a 5’-capped otide amplification and in vitro translation to occur 
structure to increase the efficiency of in vitro translation, consecutive~y, without a change in reaction conditions, The 
therefore, dikFanosine GTP ((G-S’PPPS’-G) TP) can also be solution contains a biological buffer such as MES, Bis-Tris, 
included in the reaction. so Pipes, MOPSO, HEPES, EPPS, and Tris (hydroxymethyl) 
The “cell-free in vitro translation composition” of the aminomethane salts, for example. The preferred buffer of the 
invention refers to a preparation of cell extract which allows invention is a Tris salt, specifically, Tris-HC1. The solution 
mRNA to be synthesized into protein. The extract contains of the invention also includes a magnesium source. The 
all of the factors required for protein synthesis from mRNA. magnesium source of the invention includes but is not 
The cell-free in vitro translation composition which can be 55 limited to magnesium chloride and magnesium acetate. 
incorporated into the cell-free system must be capable of Preferably, the magnesium of the invention is magnesium 
functioning (i.e., allowing translation to occur) under con- chloride (MgC1,). The solution also includes both deoxyri- 
ditions which also allow polynucleotide amplification to bonucleotide and ribonucleoside triphosphates as described 
occur. Thus, it is possible to identify acceptable cell-free in above, as substrate for the polymerase incorporation into 
vitro translation compositions by placing the composition in 60 DNA and RNA, respectively. Also included is a mixture of 
the cell-free system disclosed herein and measuring, for all 20 amino acids which are incorporated into protein 
example, the production of protein from amplified poly- during in vitro translation of the mRNA. 
nucleotide. The biological buffer of the invention is present in a 
The cell-free in vitro translation composition of the inven- concentration of from about 10 mM to about 100 mM and 
tion includes but is not limited to a composition derived 65 at pH from about 7.2 to about 8.2, most preferably 40 mM 
from archaebacterial cells, eubacterial cells, and eukaryotic and pH 7.5. The rNTPs of the invention are present from 
cells, including plant cells. Archaebacterial cells of the about 1 to about 4 mM each, preferably 2.4 mM. The dNTPs 
depends On many factors, temperature, buffer, and The cell-free system of the invention contains 
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are present at a concentration of about 0.05 to about 0.5 mM methionine was not included. The marker lane (M) shows 
each, and most preferably at about 0.2 mM. The amino acids the control, with transcription products obtained at 10 mM 
of the solution are present at a concentration of about 0.5 to MgC1, in the absence of amino acids and reticulocyte lysate. 
about 2 mM and most Preferably at 1 mM. The MgC1, is Reaction products were separated on a 5% polyacrylamide/ 
Present at about 5.0 to about 10.0 mM9 and most Preferably s 8M urea gel. Isothermal RNA amplification proceeded 
at 7.5 mM. The reaction of amplification and translation within the range of 7.5-10.0 m~ MgC1, as Seen by the 
occurs at a temperature of about 35O-40" c .  and most incorporation of [a-32P]-GTP into newly synthesized RNA 
preferably at 37" C. For example, lower temperature may be (FIG, 1). 
more desirable for primers with a high A-T base composi- 
tion. The time period of the reaction is from about 1 to about Reaction Conditions 
4 hours, preferably 2 hours. Those of skill in the art will lo 1 nM L-21 RNA (5'4runcated form of self-splicing group I 
realize that those conditions can be modified appropriately intron from Tetrahymena thermophila) (US Biochemical 
depending on particular need in order to achieve a cell-free Co., Cleveland, Ohio) 
polynucleotide amplification and translation system of the 1.0 pM (each) oligodeoxynucleotide primers 
invention. 
In addition to the solution of the invention, the other 2,4 mM (each) rNTPs (mP,CTP,GTP,UTP) components of the cell-free polynucleotide amplification 
and translation system are present in the following amounts: [a-32P1-GTP at 0.3 mCi/ml (Optional to monitor RNA 
(1) input RNA of interest is added at a final concentration 
from about lo-' to 10' nM, most preferably 1.0 nM. The Amino acid mixture minus methionine (Promega) 
concentration of message is adjusted to achieve maximum 20 35S-methionine, 1000 Ci/mmol ( h e r s h a m )  at 0.8 mCi/ml 
incorporation of amino acid into protein and may vary (optional to monitor protein synthesis) 
within the given concentrations depending on the particular 7,5 mM MgC1, message. It is a matter of routine to establish the optimal 
RNA concentration for each mRNA species. (2) The oli- 40 mM Tris-HC1, pH 7.5 
godeoxynucleotide primers are added to a final concentra- 25 Promega TNTTM rabbit reticulocyte lysate, 50% V h  
tion of 0.2 to about 10pM each and most preferably at about (Promega, Madison, Wis.) 
1.0 pM each. (3) The RNA-dependent DNA polymerase is 4 u/p1 MoMLV RT 
added to a final concentration of about 2 U/p1 to about 10 
Uipl, and preferably at 4 Uipl. (4) The DNA-dependent RNA 
polymerase is added at about 2 U/p1 to about 25 U/p1, and hours 
preferably at about 5 U/pl. (5) The cell-free in vitro trans- 30 at 37" c .  After 2 hours, the reaction was stopped by the 
lation composition is added at about 50% vo1ume:volume. addition of EDTA (10 mM final) to the tube. TE buffer was 
Additional components of the system of the invention can be added to bring the volume to a total of 50 The reaction 
added, but are not required for the use of the invention. tube was Phenol extracted followed by CHC13:isoamYl a h -  
These include: (1) potassium acetate from about 0 to about hol extraction. The aqueous layer containing the reaction 
100 mM, preferably 3 mM; (2) spermidine from about 0 to 35 Products was analyzed by PolYacrYlamide gel electrophore- 
about 0.5 mM, preferably, 0.2 mM; and (3) dithiothreitol sis (PAGE) using methods well known in the art. 
from about 0 to about 10 mM and preferably at 5 mM. 
15 0.2 mM (each) dNTPs (dATP, dCTP, dGTP, dTTP) 
uipl T7 RNA polymerase 
The tube was vortexed lightly and incubated for 
The oligodeoxynucleotide primers were as follows: 
Primer 1: 5'-CGA GTA CTC CAA AAC TAA TC-3' 
Primer2 S'-CTG CAG AAT TCT AAT ACG ACT CAC TAT AGG AGG 
GAA AAG TTA TCA GGC-3' 
4s 
The following examples are intended to illustrate but not 
limit the invention. While they are typical of those that might 
be used, other procedures known to those skilled in the art 
may alternatively be used. 
Primer 1 is a 20-mer that binds to the 3'-terminal region 
of the mRN-4, l e 5 0  nucleotides downstream from the stop 
codon, with a desired Tm for binding of about greater than 
or equal to 50" C. Primer 2 is a 48-mer that binds to the 
extreme 3' end of the cDNA that results from reverse 
50 transcription of the mRNA. It also binds with a Tm of about 
greater than or equal to 50" C. Each primer forms 12-20 
base pairs with its corresponding primer binding site. Primer 
2 contains 5 nucleotides, an Eco RI site, the promoter 
sequence for the T7 RNA polymerase, and 19 additional 
ne present invention provides a cell-free system for In vitro translation proceeded under the same set of 
po~ynuc~eotide amplification and in vitro translation that reaction conditions, as shown by the incorporation of 3 5 ~ -  
produces large quantities of protein according to the proto- methionine into newly synthesized protein. FIG. 2 shows in 
trations of MgC1, under reaction conditions as described in the Detailed Description of the invention. 
6o above for the coupled system. Also included was 0.02 pgipl 
The coupled reaction system is highly sensitive to MgC1, brome mosaic virus (BMV) genomic RNA (promega 
concentration. FIG. 1 shows isothermal amplification of Biotec), Marker lane (M) shows the control with BMV 
RNA in the Presence of varying concentrations of MgC1z. genomic RNA translation products obtained at 0.5 mM 
Reaction conditions were as described below for the coupled MgC1, in the absence of NTPs, dNTPs, oligodeoxynucle- 
system with the exception that MgC1, concentrations were 65 otide primers, MoMLV RT and T7 RNA polymerase. Reac- 
varied. The only radiolabeled substance for following RNA tion products were separated on an SDS/10% polyacryla- 
synthesis was [a-32P]-GTP in this experiment; 35S- mide stacking gel. 
EXAMPLE 1 
Determination of Optimal Conditions for Coupled 
in vitro Polynucleotide Amplification and 
Translation 55 nucleotides. 
col outlined below, Modifications are anticipated as outlined vitro Of RNA in the presence Of varying 
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Translation did not occur below 6.0 mM MgC1, in the 
coupled reaction system, even though in vitro translation 
alone operated efficiently at 0.5 mM MgC1, (Marker lane, 
M, FIG. 2). This apparent discrepancy may be due to 
complexation of Mg2+ with deoxyribo- and ribonucleoside 5 
triphosphates that are Present in the coupled reaction system. 
Such complexation could substantially reduce the available 
amount of Mg2+. RT. 
wherein the components of the system function under a 
common set of reaction conditions, and wherein DNA 
and RNA amplification and translation operate simul- 
taneously. 
tran- 
scriptase is selected from the group consisting of Moloney 
murine leukemia vims RT and avian mye~ob~astosis virus 
3. The system of claim 1, wherein the DNA dependent 
4. The system of claim 3, wherein the bacteriophage is 
selected from the group consisting of T7, T3, and SP6 
bacteriophage. 
5 .  The system of claim 1, wherein the cell-free in vitro 
translation composition is derived from a eukaryotic cell. 
plant cell, 
2, The system of claim 1, wherein the 
lo RNA polymerase is derived from a bacteriophage. EXAMPLE 2 
Coupled Isothermal RNA Amplification and in vitro 
Translation 
The following were added in a single microfuge tube 15 
under the stated reaction conditions: 
intron from Tetrahymena thermophifa) (US Biochemical 
Co., Cleveland, Ohio) 
1.0 pM (each) deoxyoligonucleotide primers 
0.2 mM (each) dNTPs (dATP, dCTP, dGTP, dTTP) 
2.4 mM (each) rNTPs (ATP,CTP,GTP,UTP) 
animal cell. 0.02 pugipl BMV genomic RNA 
[a-3zp~-GTP at 0.3 mCi/ml (optional to monitor RNA 
synthesis) reticulocyte. 
Amino acid mixture minus methionine (Promega) 
(optional to monitor protein synthesis) 
7.5 mM MgC1, 
40 mM Tris-HC1, pH 7.5 
Promega TNTTM rabbit reticulocyte lysate, 50% ViV 30 
(Promega, Madison, Wis.) 10.0 mM; 
Uipl MOMLV RT and 5 Uipl T7 RNApolymerase. The tube 
was vortexed lightly and incubated for 2 hours at 37" C. 
After 2 hours, the reaction was stopped by the addition of 35 
EDTA (10 mM final) to the tube. TE buffer was added to 
bring the volume to a total of 50 pl. The reaction tube was 
Phenol extracted followed by CHC13:isoamYl alcohol 
extraction. The aqueous layer containing the reaction prod- 
ucts was analyzed by polyacrylamide gel electrophoresis 40 
(PAGE) using methods well known in the art. The results 
showed that isothermal amplification of RNA and in vitro 
translation proceeded under the same set of reaction condi- 
tions in the same tube. 
The invention now being fully described, it will be 
apparent to one of ordinary skill in the art that various 
changes and modifications can be made without departing 
from the spirit or scope of the invention. 
nM L-21 RNA (5'-truncated form Of self-splicing group I 6, The system of claim 5,  wherein the eukaryotic cell is a 
7. The system of claim 6, wherein the plant cell is wheat 
8. The system of claim 5,  wherein the eukaryotic cell is an 
9. The system of claim 8, wherein the animal cell is a 
10. The system of claim 9, wherein the reticulocyte is a 
11. A composition, comprising: 
(a) a transcription and translation enzyme compatible 
(b) A magnesium source in a concentration of from 6.0 to 
20 cell. 
25 
S-methione, 1000 Ciimmol (Amersham) at 0.8 mCiim1 rabbit reticulocyte. 35 
biological buffer; 
The enzymes (RT and RNA polymerase) were added at (.) deoxyribonuc~eotide triphosphate; 
(dl 
(e) amino acids; 
( f )  reverse transcriptase and polynucleotide primer which 
allows the reverse transcriptase to function; and 
(g) DNA-dependent RNA polymerase and polynucleotide 
primer which allows the DNA-dependent RNA poly- 
merase to function. 
12. The composition of claim 11, wherein the biological 
13, The composition of claim 11, wherein the magnesium 
14, The composition of claim 13, wherein the salt is 
MgC1,, 
15, A method for producing polypeptide comprising 
amplifying and translating a eukaryotic polynucleotide 
I claim: which encodes the polypeptide using a cell-free system of 
1. A cell-free system for amplification and translation of claim 1, 
16. The method of claim 15, wherein the polynucleotide 
reverse transcriptase, polynucleotide primer which allows is mRNA. 
the reverse transcriptase to function, DNA-dependent 17. The method of claim 15, wherein the polynucleotide 
RNA polymerase, polynucleotide primer which allows 55 is DNA. 
the DNA-dependent RNA polymerase to function, 18. The method of claim 17, wherein the DNA is cDNA. 
deoxyribonucleotide triphosphate, ribonucleoside 19. A cell-free system according to claim 1 wherein the 
triphosphate, and a cell free in vitro translation com- 
position comprising a magnesium source in a concen- 
tration of from 6.0 to 10.0 mM, 
triphosphate; 
buffer is a tris(hydroxymethy~) aminomethane salt, 
45 source is a salt. 
prokaryotic polynucleotide sequences comprising: 
magnesium source is MgC1,. 
* * * * *  
